Arrowhead Pharmaceuticals, Inc. (ARWR) Report Analysis
Corporate Events
Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
2022-06-27 10:00:00
Takeda and Arrowhead Pharmaceuticals Inc. announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD) were recently published in the New England Journal of Medicine (NEJM) andpresented in an oral presentation at The International Liver Congress™ 2022 - The Annual Meeting of the European Association for the Study of the Liver (EASL). The NEJM article was published online ahead of print [2] and is titled, “Fazirsiran for Liver Disease Associated with Alpha-1 Antitrypsin Deficiency.” The EASL presentation was titled, “Reduction of Intra-hepatic Z-AAT Synthesis by Fazirsiran Decreases Globule Burden and Improves Histological Measures of Liver Disease in Adults with Alpha-1 Antitrypsin Deficiency". Fazirsiran is a potential first-in-class investigational RNA interference (RNAi) therapy designed to reduce the production of mutant alpha-1 antitrypsin protein (Z-AAT) as a potential treatment for the rare genetic liver disease associated with AATD. Z-AAT accumulation is believed to be the cause of progressive liver disease in patients with AATD. Reducing production of the inflammatory Z-AAT protein is expected to halt the progression of liver disease and potentially allow the liver to regenerate and repair. Fazirsiran was granted Breakthrough Therapy Designation (BTD) in July 2021 and Orphan Drug Designation in February 2018 for the treatment of AATD from the US FDA.
Arrowhead Pharmaceuticals, Inc. Presents at LifeSci Partners Genetic Medicines Symposium, Jun-29-2022 01:00 PM
2022-06-17 02:35:00
Arrowhead Pharmaceuticals, Inc. Presents at LifeSci Partners Genetic Medicines Symposium, Jun-29-2022 01:00 PM. Speakers: Christopher R. Anzalone, CEO, President & Director.
LifeSci Partners, LifeSci Partners Genetic Medicines Symposium, Jun 28, 2022 through Jun 29, 2022
2022-06-16 21:17:00
LifeSci Partners, LifeSci Partners Genetic Medicines Symposium, Jun 28, 2022 through Jun 29, 2022.
Arrowhead Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 08:30 AM
2022-06-07 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 08:30 AM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Vincent Anzalone, Head of Investor Relations & VP.
Arrowhead Pharmaceuticals, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 11:20 AM
2022-06-07 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 11:20 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Vincent Anzalone, Head of Investor Relations & VP.
Arrowhead Pharmaceuticals, Inc. Presents at The International Liver Congress 2022, Jun-22-2022
2022-06-07 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at The International Liver Congress 2022, Jun-22-2022 . Venue: London, United Kingdom.
Arrowhead Pharmaceuticals, Inc. Breaks Ground on New Manufacturing Facility
2022-05-09 14:30:00
Arrowhead Pharmaceuticals, Inc. held a groundbreaking ceremony in Verona, WI, on the site which will house a new approximately 160,000 square foot drug manufacturing facility and an approximately 125,000 square foot laboratory and office facility to support process development and analytical activities. The Company also announced that it received awards for up to $16 million in tax increment financing from the city of Verona, and up to $2.5 million in refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation as incentives to invest in the local community and create new jobs. Major construction project team members include Eppstein Uhen Architects, DPS Group, D’Onofrio Kottke & Associates, Smocke & Associates, and Vogel Bros. Building Co. Completion of the lab and office space is anticipated in 2023 and completion of the manufacturing facility is expected in 2024.
Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors
2022-05-02 11:31:00
Arrowhead Pharmaceuticals Inc. announced that the board of directors appointed veteran pharmaceutical industry executive Victoria Vakiener, as an independent director of the company, with a term beginning effective May 2, 2022. Ms. Vakiener currently serves on the board of directors of Chimerix, a clinical-stage biopharmaceutical company.
Arrowhead Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-17-2022 04:35 PM
2022-05-02 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-17-2022 04:35 PM. Venue: InterContinental New York, Barclay hotel, New York, New York, United States. Speakers: Christopher R. Anzalone, CEO, President & Director.
Arrowhead Pharmaceuticals, Inc. Presents at American Thoracic Society 2022 International Conference, May-13-2022
2022-05-02 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at American Thoracic Society 2022 International Conference, May-13-2022 . Venue: San Francicso, California, United States. Speakers: David Kasahara, Senior Scientist III, Biology.
Arrowhead Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-25-2022 12:15 PM
2022-05-02 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-25-2022 12:15 PM. Venue: Lotte New York Palace, New York City, New York, United States. Speakers: Vincent Anzalone, Head of Investor Relations & VP.
Arrowhead Pharmaceuticals Inc. Doses the First Patients in the Phase 2 GATEWAY Clinical Study of Investigational ARO-ANG3 for the Treatment of Patients with Homozygous Familial Hypercholesterolemia
2022-04-26 11:30:00
Arrowhead Pharmaceuticals Inc. announced that it has dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). ARO-ANG3 is the company’s investigational RNA interference (RNAi) therapeutic designed to silence the hepatic expression of angiopoietin-like protein 3 (ANGPTL3), a liver synthesized inhibitor of lipoprotein lipase and endothelial lipase, being developed as a treatment for patients with mixed dyslipidemia. GATEWAY, also called AROANG3-2003 (NCT05217667), is an open-label Phase 2 clinical study to evaluate the efficacy and safety of investigational ARO-ANG3 in up to 16 subjects with HoFH. Two dose levels of ARO-ANG3 (200 mg and 300 mg) will be evaluated in subjects with documented HoFH based on genotype or clinical criteria, and with fasting LDL-C greater 100 mg/dL (2.59 mmol/L) and fasting triglycerides less than 300 mg/dL (3.39 mmol/L) at screening. Subjects will receive a subcutaneous injection of ARO-ANG3 on day 1 and day 84 and may be eligible to participate in an optional open-label extension study. The primary objective of the GATEWAY study is to evaluate the efficacy and safety of ARO-ANG3 in subjects with HoFH and the primary endpoint is the percent change in fasting calculated LDL-C from baseline to week 24. Arrowhead recently completed enrollment in the ongoing Phase 2b ARCHES-2 clinical study evaluating ARO-ANG3 in more than 180 patients with elevated low-density lipoprotein LDL-C and triglycerides. The completion of this study is anticipated around the end of this year and the company intends to release topline data in the first half of 2023.
Arrowhead Pharmaceuticals and Vivo Capital Form Joint Venture, Visirna Therapeutics to Expand the Reach of Innovative Medicines in Greater China
2022-04-25 11:30:00
Arrowhead Pharmaceuticals Inc. announced that it has formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the reach of innovative medicines in Greater China. Funds affiliated with Vivo provided initial funding of $60 million to Visirna and Vivo will leverage its network in Greater China to support Visirna, particularly in recruiting Visirna’s leadership team and actively engaging in corporate development, clinical, and regulatory strategies in the region. Arrowhead has a majority stake in Visirna after accounting for shares reserved for the employee stock ownership plan and is further eligible to receive potential royalties on commercial sales. Arrowhead also received the right to appoint members to the Visirna board of directors. Visirna will be headquartered in Shanghai, and recruitment of management and development staff is currently underway.
Arrowhead Pharmaceuticals, Inc. Presents at TIDES (Oligonucleotide & Peptide Therapeutics), May-05-2022
2022-04-23 17:57:00
Arrowhead Pharmaceuticals, Inc. Presents at TIDES (Oligonucleotide & Peptide Therapeutics), May-05-2022 . Venue: Boston, Massachusetts, United States. Speakers: Michael Lawler, Director of Chemistry.
I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022
2022-04-23 07:45:00
I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022. Venue: Boston, Massachusetts, United States.
Arrowhead Pharmaceuticals, Inc., Q2 2022 Earnings Call, May 10, 2022
2022-04-20 20:00:00
Arrowhead Pharmaceuticals, Inc., Q2 2022 Earnings Call, May 10, 2022
Arrowhead Pharmaceuticals, Inc. Presents at 31st Conference of the Asian Pacific Association for the Study of Liver, Mar-30-2022
2022-04-01 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at 31st Conference of the Asian Pacific Association for the Study of Liver, Mar-30-2022 . Venue: Seou, South Korea.
Arrowhead Pharmaceuticals, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022
2022-04-01 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 . Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States.
Arrowhead Pharmaceuticals, Inc. Presents at 2022 FDA/DIA Oligonucleotide-based Therapeutics Conference, Apr-25-2022
2022-04-01 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at 2022 FDA/DIA Oligonucleotide-based Therapeutics Conference, Apr-25-2022 . Venue: Bethesda North Marriott, Hotel & Conference Center, 5701 Marinelli Road, Rockvillle, Maryland, United States.
The European Association for the Study of the Liver, the International Liver Congress 2022, Jun 22, 2022 through Jun 25, 2022
2022-03-30 21:14:00
The European Association for the Study of the Liver, The International Liver Congress 2022, Jun 22, 2022 through Jun 25, 2022. Venue: London, United Kingdom.
Asian Pacific Association for the Study of Liver, 31st Conference of the Asian Pacific Association for the Study of Liver, Mar 30, 2022 through Apr 03, 2022
2022-03-30 11:30:00
Asian Pacific Association for the Study of Liver, 31st Conference of the Asian Pacific Association for the Study of Liver, Mar 30, 2022 through Apr 03, 2022. Venue: Seou, South Korea.
Arrowhead Pharmaceuticals, Inc. - Special Call
2022-03-24 11:30:00
To Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
Arrowhead Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-2022 10:40 AM
2022-03-22 05:03:00
Arrowhead Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-2022 10:40 AM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Christopher R. Anzalone, CEO, President & Director.
Drug Information Association, Inc., U.S. Food and Drug Administration, 2022 FDA/DIA Oligonucleotide-based Therapeutics Conference, Apr 25, 2022 through Apr 27, 2022
2022-03-20 11:59:00
Drug Information Association, Inc., U.S. Food and Drug Administration, 2022 FDA/DIA Oligonucleotide-based Therapeutics Conference, Apr 25, 2022 through Apr 27, 2022. Venue: Bethesda North Marriott, Hotel & Conference Center, 5701 Marinelli Road, Rockvillle, Maryland, United States.
RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022
2022-03-04 01:06:00
RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022. Venue: InterContinental New York, Barclay hotel, New York, New York, United States.
UBS Investment Bank, UBS Global Healthcare Conference, May 23, 2022 through May 25, 2022
2022-03-03 04:07:00
UBS Investment Bank, UBS Global Healthcare Conference, May 23, 2022 through May 25, 2022. Venue: Lotte New York Palace, New York City, New York, United States.
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022
2022-02-17 10:42:00
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022
2022-02-14 21:00:00
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.
The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022
2022-02-08 07:31:00
The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
Arrowhead Pharmaceuticals, Inc., Q1 2022 Earnings Call, Feb 02, 2022
2022-01-21 21:00:00
Arrowhead Pharmaceuticals, Inc., Q1 2022 Earnings Call, Feb 02, 2022
American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022
2022-01-13 18:45:00
American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022. Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States.
Arrowhead Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $19.17235 million.
2021-12-22 00:00:00
Arrowhead Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $19.17235 million. Security Name: Common Stock Securities Offered: 273,500 Transaction Features: ESOP Related Offering
Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
2021-12-20 12:30:00
Arrowhead Pharmaceuticals, Inc. announced that it has completed a transaction to purchase 13 acres of land in the Verona Technology Park in Verona, WI, which is planned to be the site of an approximately 140,000 square foot drug manufacturing facility and an approximately 115,000 square foot laboratory and office facility to support process development and analytical activities. Arrowhead intends to invest between $200 million and $250 million into the buildout of the facilities. The Company expects that the new facilities will result in the creation of approximately 250 new jobs in the local area. Construction is scheduled to begin in the first quarter of 2022. Arrowhead will continue to operate additional research and development facilities in Madison, WI, and San Diego, CA.
Arrowhead Pharmaceuticals, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-02-2021 01:00 PM
2021-11-30 21:00:00
Arrowhead Pharmaceuticals, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-02-2021 01:00 PM. Speakers: Christopher R. Anzalone, CEO, President & Director.
CVCT, Overcome, 18th Global Cardio Vascular Clinical Trialists Forum, Dec 02, 2021 through Dec 05, 2021
2021-11-30 21:00:00
CVCT, Overcome, 18th Global Cardio Vascular Clinical Trialists Forum, Dec 02, 2021 through Dec 05, 2021.
Arrowhead Pharmaceuticals, Inc. Presents at 18th Global Cardio Vascular Clinical Trialists Forum, Dec-03-2021
2021-11-30 21:00:00
Arrowhead Pharmaceuticals, Inc. Presents at 18th Global Cardio Vascular Clinical Trialists Forum, Dec-03-2021 . Speakers: James C. Hamilton, Senior VP of Discovery & Translational Medicine.
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with Gsk for Aro-Hsd
2021-11-22 21:00:00
Arrowhead Pharmaceuticals, Inc. announced that it entered into an exclusive license agreement with GlaxoSmithKline under which GSK will develop and commercialize ARO-HSD, Arrowhead’s investigational RNA interference therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis. Under the terms of the agreement, Arrowhead will receive an upfront payment of $120 million and is eligible for additional payments of $30 million at the start of Phase 2 and $100 million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to Arrowhead of up to $190 million at first commercial sale, and up to $590 million in sales-related milestone payments. Arrowhead is further eligible to receive tiered royalties on net product sales. GSK will receive an exclusive license to develop and commercialize ARO-HSD in all territories except Greater China, which will be retained by Arrowhead. GSK will be wholly responsible for further clinical development and commercialization, outside of Greater China. The transaction is expected to close in the first quarter of 2022, subject to customary closing conditions and clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
Arrowhead Pharmaceuticals, Inc. Announces JNJ-75220795 in Development for Nash
2021-11-17 14:00:00
Arrowhead Pharmaceuticals Inc. announced that its collaborator, Janssen Pharmaceuticals, Inc., (Janssen) one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has disclosed its collaboration with Arrowhead on investigational compound JNJ-75220795, which is in a Phase 1 clinical study. JNJ-75220795 is an investigational siRNA therapeutic developed using Arrowhead’s proprietary TRIMTM platform and designed to reduce expression in the liver of patatin like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with non-alcoholic steatohepatitis (NASH). PNPLA3 has strong genetic and preclinical validation as a driver of fat accumulation and damage in the livers of patients who carry the common I148M mutation. Arrowhead entered into a research collaboration and option agreement with Janssen in October 2018, which resulted in collaboration on JNJ-75220795.
Arrowhead Pharmaceuticals, Inc. Presents New Clinical Data on ARO-APOC3 at AHA 2021
2021-11-15 12:30:00
Arrowhead Pharmaceuticals Inc. announced additional Phase 1/2 clinical data on ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic targeting apolipoprotein C-III (APOC3) being developed as a treatment for patients with hypertriglyceridemia (HTG), severe hypertriglyceridemia (sHTG), and familial chylomicronemia syndrome (FCS), at the American Heart Association (AHA) Scientific Sessions 2021. Four genetically confirmed FCS patients received 50 mg ARO-APOC3 and 26 multifactorial chylomicronemia (MCM or non-FCS) patients received 10, 25, 50, or 100 mg ARO-APOC3 on days 1 and 29. Since similar responses were observed among MCM pts, results were pooled across dose levels. Safety and pharmacodynamic responses were examined. Maximal mean and median changes from baseline for APOC3, triglycerides (TG), non-HDL-C, and HDL-C were reported. Key data presented include the following: Summary: In patients with FCS compared with non-FCS, ARO-APOC3 achieved similar levels of reduction of APOC3 and changes in key lipid parameters; In patients with FCS compared with non-FCS, safety parameters were similar and comparable; In patients with sHTG, ARO-APOC3 was well tolerated, and consistently decreased APOC3, TG, and non-HDL-C, and increased HDL-C, independent of underlying genetic cause of HTG; ARO-APOC3 may represent a promising RNAi therapeutic for the treatment of sHTG with infrequent dosing of every 3 months or every 6 months. Pharmacodynamic Response: APOC3 was reduced by 98% in FCS patients and 96% in MCM patients; Both groups showed similar maximum median reductions in TG of 91% and 90%, respectively; Non-HDL-C was reduced by 58% and 49%, respectively; and HDL-C increased by 152% and 111%, respectively. Safety: ARO-APOC3 was generally well tolerated; No treatment emergent adverse event (TEAE)-related study drug discontinuation, dose interruptions, or premature study withdrawals; No clear pattern of an increased frequency or intensity of adverse events with increasing dose level; TEAEs and the safety parameters were similar and comparable with FCS compared to non-FCS subjects; and 2 serious adverse events (chest pain and acute pancreatitis) not related to ARO-APOC3 in 2 subjects in the non-FCS group – both subjects completed the study.
American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022
2021-11-13 09:53:00
American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022. Venue: San Francicso, California, United States.
Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting
2021-11-12 12:30:00
Arrowhead Pharmaceuticals Inc. announced additional interim clinical data from AROHSD1001, an ongoing Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH). The data were presented in a late-breaking poster at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD), taking place November 12-15, 2021. Key data presented include the following: Pharmacodynamic Response: Dose-dependent pharmacodynamic effect on hepatic HSD17B13 mRNA was observed in all patients. At 200 mg, all patients showed greater than 90% mRNA reductions. Hepatic HSD17B13 protein levels were reduced at all ARO-HSD dose levels, with multiple measurements below the assay’s lower limit of quantitation. Decreases in ALT and AST were observed at doses of 100 mg? ARO-HSD and greater. 9 of 18 patients had liver fat reductions on MRI-PDFF of 4-41%. 6 of 18 patients had reduction in liver stiffness (kPa) on FibroScan of 4-37%. Pharmacodynamic effect was not impacted by HSD17B13 (rs72613567, T>TA) or PNPLA3 (rs738409, C>G) mutations. Safety: ARO-HSD was well-tolerated in patients, with no ARO-HSD-related serious adverse events reported, no adverse events leading to drug discontinuations, and no ARO-HSD-related clinically significant adverse laboratory trends observed, One treatment emergent serious adverse event of soft tissue injury that required hospitalization was reported in cohort 4b. This event was considered unrelated to study drug.
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
2021-11-12 12:30:00
Arrowhead Pharmaceuticals Inc. announced additional interim clinical data from the ongoing AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, also known as TAK-999, the company’s second-generation investigational RNA interference (RNAi) therapeutic being co-developed with Takeda Pharmaceutical Company Limited ("Takeda”) as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD). The data were presented in a late-breaking poster at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD), taking place November 12-15, 2021. Key data presented includes: Pharmacodynamic Response: ARO-AAT treatment allowed clearance of liver Z-AAT protein. Total liver Z-AAT was reduced by 72-100%. ARO-AAT treatment improved liver fibrosis. 6 of 14 patients had a 1 point or greater improvement in METAVIR fibrosis stage from baseline to week 24 or 48. 6 of 14 patients had no change from baseline to week 24 or 48. 2 of 14 patients had an increase from F2 at baseline to F3 at week 48, although both patients had profound reduction in PAS+D globule burden and reduced ALT and GGT after treatment. ARO-AAT treatment reduced histological globule burden. 13 of 13 patients had a 1 point or greater reduction in PAS+D globule burden. ARO-AAT treatment improved biomarkers of liver health. Mean reduction from baseline ranged from 42% to 56% for ALT and from 33% to 54% for GGT at week 28 and week 72. All groups showed normalized ALT and GGT following treatment Safety. No treatment emergent adverse events leading to drug discontinuation, dose interruptions, or study withdrawal. No treatment emergent adverse events related to change in pulmonary status or pulmonary function were reported. No clinically meaningful changes in ppFEV1 from baseline (mean 85% [N=16]) were observed at Week 40 (mean 81% [N=15]) or at Week 72 (mean 84% [N=4]). Four SAEs were reported: EBV-related myocarditis, diverticulitis, dyspnea, and vestibular neuronitis, all of which involve confounding factors or alternative etiology.
Arrowhead Pharmaceuticals, Inc., 2021 Earnings Call, Nov 22, 2021
2021-11-01 20:00:00
Arrowhead Pharmaceuticals, Inc., 2021 Earnings Call, Nov 22, 2021
Arrowhead Pharmaceuticals, Inc. Presents at American Heart Association (AHA) Scientific Session, Nov-13-2021
2021-11-01 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at American Heart Association (AHA) Scientific Session, Nov-13-2021 .
Arrowhead Pharmaceuticals, Inc. Presents at AASLD The Liver Meeting, Nov-12-2021
2021-11-01 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at AASLD The Liver Meeting, Nov-12-2021 .
Arrowhead Pharmaceuticals, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 11:50 AM
2021-11-01 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 11:50 AM. Venue: London, United Kingdom. Speakers: Christopher R. Anzalone, CEO, President & Director.
Arrowhead Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-30-2021
2021-11-01 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-30-2021 . Venue: New York, New York, United States. Speakers: Christopher R. Anzalone, CEO, President & Director.
Arrowhead Pharmaceuticals Inc. Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
2021-10-25 11:30:00
Arrowhead Pharmaceuticals Inc. announced that it has filed an application for clearance to begin a phase 1/2a clinical trial of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with various complement mediated diseases. An application for approval of the clinical trial is being submitted to a local Ethics Committee and to the New Zealand Medicines and Medical Devices Safety Authority for review by the Standing Committee on Therapeutic Trials. Pending clearance, the company intends to proceed with AROC3-1001, a phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3 in up to 24 adult healthy volunteers and in up to 24 adult patients with paroxysmal nocturnal hemoglobinuria and up to 14 adult patients with complement-mediated renal disease.
American Heart Association, American Heart Association (AHA) Scientific Session, Nov 13, 2021 through Nov 15, 2021
2021-10-19 14:15:00
American Heart Association, American Heart Association (AHA) Scientific Session, Nov 13, 2021 through Nov 15, 2021.
Arrowhead Pharmaceuticals, Inc. - Special Call
2021-10-12 20:00:00
To discuss the current treatment landscape and unmet medical need in treating patients with complement mediated renal and hematological diseases and to discuss the biology of the target, preclinical data generated to date, and clinical plans for ARO-C3
Arrowhead Pharmaceuticals, Inc. Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
2021-09-30 11:30:00
Arrowhead Pharmaceuticals, Inc. announced that it has dosed the first patient in AROAPOC3-2002, a Phase 2b clinical study of ARO-APOC3 in adults with mixed dyslipidemia. ARO-APOC3 is the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with severe hypertriglyceridemia (SHTG), mixed dyslipidemia, and familial chylomicronemia syndrome (FCS). Arrowhead intends to initiate a Phase 3 study of ARO-APOC3 in patients with FCS in the fourth quarter of 2021. AROAPOC3-2002 (NCT04998201) is a double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of ARO-APOC3 in adults with mixed dyslipidemia. Four dose cohorts of ARO-APOC3 will be evaluated against placebo in participants who had the following at screening: (i) elevated triglycerides (TG) greater than or equal to 150 mg/dL (1.69 mmol/L) but less than 499 mg/dL (5.61 mmol/L), and (ii) non-high-density lipoprotein cholesterol (non-HDL-C) greater than or equal to 100 mg/dL (2.59 mmol/L) or low-density lipoprotein cholesterol (LDL-C) greater than or equal to 70 mg/dL (1.8 mmol/L) at screening. A total of approximately 320 participants will be enrolled in the study. All dose cohorts will enroll in parallel with approximately 80 participants per dose cohort, randomly assigned in a 3:1 ratio to receive ARO-APOC3 or placebo. In three cohorts (10 mg, 25 mg, 50 mg), each participant will receive a subcutaneous injection on day 1 and week 12 for a total of 2 injections. In one additional 50 mg cohort, each participant will receive a subcutaneous injection on day 1 and week 24 for a total of 2 injections. The duration of the study is approximately 54 weeks from screening to the week 48 end-of-study examination. The primary objective of the study is to evaluate the safety and efficacy of ARO-APOC3 in adults with mixed dyslipidemia and to select a dose and dosing regimen for later stage clinical studies in this patient population.
Arrowhead Pharmaceuticals, Inc. Presents at Chardan's 5th Annual Genetic Medicines Conference, Oct-04-2021 04:30 PM
2021-09-29 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at Chardan's 5th Annual Genetic Medicines Conference, Oct-04-2021 04:30 PM. Speakers: Vincent Anzalone, Vice President of Investor Relations.
Arrowhead Pharmaceuticals, Inc. Presents at H.C. Wainwright 5th Annual NASH Investor Conference, Oct-12-2021 02:00 PM
2021-09-29 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at H.C. Wainwright 5th Annual NASH Investor Conference, Oct-12-2021 02:00 PM. Speakers: James C. Hamilton, Senior VP of Discovery & Translational Medicine.
H.C. Wainwright & Co., LLC, H.C. Wainwright 5th Annual NASH Investor Conference, Oct 12, 2021
2021-09-28 20:00:00
H.C. Wainwright & Co., LLC, H.C. Wainwright 5th Annual NASH Investor Conference, Oct 12, 2021.
Arrowhead Pharmaceuticals, Inc. Earns $10 Million Phase 1 Milestone Payment
2021-09-28 11:30:00
Arrowhead Pharmaceuticals Inc. announced that it earned a $10 million milestone payment from Janssen Pharmaceuticals, Inc., (Janssen) part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The milestone payment was earned after Janssen dosed the fifth patient in a Phase 1 clinical study of ARO-JNJ1, an investigational RNAi therapeutic candidate which utilizes Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform. Arrowhead entered into a license and collaboration agreement, and into a research collaboration and option agreement, with Janssen in October 2018. Arrowhead is eligible for additional payments when future milestones are met and is also eligible for royalties on commercial sales of ARO-JNJ1.
American Association For The Study Of Liver Diseases, AASLD the Liver Meeting, Nov 12, 2021 through Nov 15, 2021
2021-09-20 00:00:00
American Association For The Study Of Liver Diseases, AASLD The Liver Meeting, Nov 12, 2021 through Nov 15, 2021.
Arrowhead Pharmaceuticals, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-09-2021
2021-09-01 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-09-2021 . Venue: New York, United States.
Arrowhead Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-29-2021 09:20 AM
2021-09-01 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-29-2021 09:20 AM. Venue: New York, United States. Speakers: Christopher R. Anzalone, CEO, President & Director.
Arrowhead Pharmaceuticals, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM
2021-09-01 11:30:00
Arrowhead Pharmaceuticals, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: Christopher R. Anzalone, CEO, President & Director.
James Hassard, the Former Chief Commercial Officer of Arrowhead Pharmaceuticals, Inc. Is No Longer with the Company
2021-08-27 20:11:00
Effective August 23, 2021, James Hassard, the former Chief Commercial Officer of Arrowhead Pharmaceuticals, Inc. is no longer with the Company.
Arrowhead Pharmaceuticals, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 04:55 PM
2021-08-26 17:20:00
Arrowhead Pharmaceuticals, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 04:55 PM. Speakers: Christopher R. Anzalone, CEO, President & Director, Vincent Anzalone, Vice President of Investor Relations.
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021
2021-08-24 20:29:00
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.
Chardan Capital Markets, LLC, Chardan's 5th Annual Genetic Medicines Conference, Oct 04, 2021 through Oct 05, 2021
2021-08-24 14:20:00
Chardan Capital Markets, LLC, Chardan's 5th Annual Genetic Medicines Conference, Oct 04, 2021 through Oct 05, 2021.
Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021
2021-08-10 13:03:00
Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.
Arrowhead Pharmaceuticals, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-09-2021 03:00 PM
2021-08-04 12:33:00
Arrowhead Pharmaceuticals, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-09-2021 03:00 PM. Speakers: Christopher R. Anzalone, CEO, President & Director, Vincent Anzalone, Vice President of Investor Relations.
Arrowhead Pharmaceuticals, Inc., Q3 2021 Earnings Call, Aug 05, 2021
2021-07-14 11:30:00
Arrowhead Pharmaceuticals, Inc., Q3 2021 Earnings Call, Aug 05, 2021
Arrowhead Pharmaceuticals, Inc. Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
2021-07-06 11:30:00
Arrowhead Pharmaceuticals Inc. announced positive interim results from the first two cohorts of AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC). ARO-HIF2 is the first tumor-targeted investigational medicine to utilize Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform in a clinical trial. Arrowhead is currently enrolling the third planned patient cohort of AROHIF21001 and the company intends to present additional data at an appropriate medical congress. Key Results from AROHIF21001: 17 patients have been enrolled to receive intravenous injections of 225 mg weekly (cohort 1, n=7) or 525 mg weekly (cohort 2, n=10). The study has progressed to a dose of 1050 mg weekly (cohort 3), which is currently enrolling patients. HIF2a protein H-score was assessed via immunohistochemistry. 9 of 17 patients had tumor samples that could be evaluated. 7 of 9 demonstrated reductions in HIF2a. Reductions ranged from -9% to -82% with a mean reduction of -48%. Efficacy was assessed by Response Evaluation. Criteria in Solid Tumors (RECIST). In cohort 2, one subject had a partial response with approximately 65% tumor shrinkage and 5 had a best response of stable disease. 4 subjects in cohort 2 remain on drug with stable disease with treatment durations between 12 and 24 weeks. To date, investigational ARO-HIF2 has been generally well tolerated at doses of up to 525 mg weekly. No cases of anemia related to drug have been reported. AROHIF21001 (NCT04169711) is a Phase 1b dose-finding clinical study in patients with advanced ccRCC to evaluate the safety of ARO-HIF2 and to determine the recommended Phase 2 dose. Secondary objectives include the assessment of pharmacokinetics and preliminary efficacy, based on Response Evaluation Criteria in Solid Tumors (RECIST). Exploratory objectives for AROHIF21001 are post-dose tumoral expression of HIF genes in response to treatment with ARO-HIF2, change in Karnofsky Performance Status (KPS), correlation of tumor response based on RECIST with tumor HIF2a gene expression and tumor integrin expression, correlation of integrin expression with changes in HIF gene expression, evaluation of serum biomarkers of ARO-HIF2 activity, correlation of RCC-related gene expression to ARO-HIF2 activity, and evaluation of plasma and urine metabolites.
Arrowhead Pharmaceuticals, Inc. Pauses ARO-ENaC Phase 1/2 Clinical Study
2021-07-02 11:30:00
Arrowhead Pharmaceuticals Inc. notified regulatory agencies, institutional review boards, and investigators that effective immediately it is voluntarily pausing AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF), after receiving a preliminary update from an ongoing chronic toxicology study in rats that contained unexpected signals of local lung inflammation. The company has instructed investigators to pause new screening, enrollment, and any further dosing of investigational ARO-ENaC pending additional data from the ongoing chronic rat toxicology study and an additional ongoing chronic primate toxicology study. AROENaC1001 (NCT04375514) is a Phase 1/2 dose-escalating study to evaluate the safety, tolerability, and pharmacokinetic effects of investigational ARO-ENaC in normal healthy volunteers and to evaluate the safety, tolerability, and efficacy in patients with CF.
BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021
2021-07-01 10:09:00
BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.
Arrowhead Pharmaceuticals, Inc. Initiates Phase 2B Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
2021-06-30 11:30:00
Arrowhead Pharmaceuticals Inc. announced that it has dosed the first patient in AROANG3-2001, a Phase 2b clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with mixed dyslipidemia. AROANG3-2001 (NCT04832971 [1]) is a double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of investigational ARO-ANG3 in adults with mixed dyslipidemia. Three dose levels of ARO-ANG3 (50 mg, 100 mg, and 200 mg) will be evaluated against placebo in participants with mixed dyslipidemia who had the following at screening: (i) low-density lipoprotein cholesterol (LDL-C) greater than or equal to 70 mg/dL (1.8 mmol/L) or non-high-density lipoprotein cholesterol (non-HDL-C) greater than or equal to 100 mg/dL (2.59 mmol/L) and (ii) mean fasting triglycerides (TG) greater than or equal to 150 mg/dL (1.69 mmol/L) but less than 499 mg/dL (5.61 mmol/L). A total of approximately 180 participants will be enrolled in the study. All dose cohorts will enroll in parallel with 60 participants per cohort randomly assigned in a 3:1 ratio to receive a subcutaneous injection of ARO-ANG3 or placebo on day 1 and week 12. The duration of the study is approximately 42 weeks from screening to the week 36 end-of-study examination. After completing the week 36 visit, participants will be eligible to continue in an open-label extension study. The primary objective of the AROANG3-2001 study is to evaluate the safety and efficacy of ARO-ANG3 in adults with mixed dyslipidemia and select a dosing regimen for later stage clinical studies in this patient population.
Fundamental Summary
According to their recent financial report, which was published on 2022-05-10, Arrowhead Pharmaceuticals had several impressive financial metrics that should make them more attractive than their peers going forward. Their positive income, growth, and value factors indicate that it is likely to continue to produce impressive results for the foreseeable future, as well. This relative strength should allow Arrowhead Pharmaceuticals to continue to perform well even in a tough market. As such, Arrowhead Pharmaceuticals received an overall score of 74 and a HOLD recommendation.
Arrowhead Pharmaceuticals reported earnings results for the second quarter and six months ended March 31, 2022. For the second quarter, the company reported sales was USD 151.81 million compared to USD 32.81 million a year ago. Net income was USD 44.37 million compared to net loss of USD 26.82 million a year ago. Diluted earnings per share from continuing operations was USD 0.41 compared to diluted loss per share from continuing operations of USD 0.26 a year ago.For the six months, sales was USD 179.24 million compared to USD 54.11 million a year ago. Net loss was USD 18.51 million compared to USD 47.55 million a year ago. Diluted loss per share from continuing operations was USD 0.18 compared to USD 0.46 a year ago.
Business Description
Arrowhead Pharmaceuticals develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals was incorporated in 1989 and is headquartered in Pasadena, California.
Sector Overview
Arrowhead Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Arrowhead Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -24.9 | 43.7% | 53 | |
| Net Cashflow | -286.0 | -491.7% | 60 | |
| Capital Expenditure | -22.7 | 9.6% | 87 | |
| Asset Turnover | 0.4 | 42.1% | 96 | |
| Free Cashflow | -0.7 | -160.4% | 39 |
* All values are TTM
The below chart reflects Arrowhead Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Arrowhead Pharmaceuticals's peer average final assessment score stands on 63.0, Arrowhead Pharmaceuticals's score is 74.
- ARWR
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Arrowhead Pharmaceuticals's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Arrowhead Pharmaceuticals's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 31.
5D MA
33.3
50D MA
35.59
200D MA
53.08
MACD
-0.8
RSI
44.99
STOCH
70.16
Balance Sheet Analysis
Arrowhead Pharmaceuticals appears likely to maintain its strong balance sheet metrics and momentum going forward. Arrowhead Pharmaceuticals publishes solid book value factor metrics in this report. Price to book ratio (P/B) now sits at 7.9 and represents a -57.6% change from the previous report. The company's book value factor metrics are even more remarkable when compared to their peers. Consequently, their book value factors movement received a grade of 73. Also, In terms of liabilities, Arrowhead Pharmaceuticals published good numbers. Their reported liabilities were 251.3, representing a -5.5% change from the previous report. These liabilities changes appear balanced compared to their peers and project the message that management is capable and focused on balancing asset growth, resource allocation, and growing liabilities. Therefore, we rated their liabilities movement with a score of 72. On the other hand, Equity, jumped out as looking problematic. Arrowhead Pharmaceuticals reported weak equity changes momentum this period. At filing, equity was reported as 452.3, representing 21.4% change from the previous report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. This performance is significantly less impressive than its peers and competitors. Therefore, their equity movement component earned a score of 63. Therefore, we scored its balance sheet a 71.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 703.6 | 10.2% | 71 |
| Liabilities | 251.3 | -5.5% | 72 |
| Price to Book | 7.9 | -57.6% | 73 |
| Cash & Equivalents | 86.4 | -5.7% | 65 |
| Equity | 452.3 | 21.4% | 63 |
The below chart describes Arrowhead Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Arrowhead Pharmaceuticals received a balance sheet score of 71, the average of its peers stands on 63.0.
- ARWR
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 3 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 4 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 5 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 7 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 16 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 18 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 20 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 21 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 22 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 23 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 24 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 25 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 26 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 27 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 28 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 29 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 38 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 45 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 51 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 53 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 56 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 64 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 65 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 67 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 68 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 77 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 78 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 81 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 93 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
EBITDA and Return Factors stand out as the most significant drivers of Arrowhead Pharmaceuticals's income statement's strength. Arrowhead Pharmaceuticals's management was effective in improving its EBIDTA, which now sits at -98.3 and represents a 41.7% change from the last reporting period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. The company's EBITDA movement, therefore, received a grade of 92. Also, Return factors metrics and ratios were exceptional in this report. Arrowhead Pharmaceuticals reported a return on equity (ROE) ratio of -24.9, representing a change of 43.7% from the last report. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 53. On the other hand, Revenue Efficiency, jumped out as looking rather underwhelming. Arrowhead Pharmaceuticals reported discouraging numbers for its revenue efficiency. As of the current filing, they were reported as 263.4 and represented 82.4% change from the previous period. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency, specifically in contrast to their industry peers', isn't encouraging. As a result, their revenue efficiency earned a score of 38. Therefore, their income statement earned a grade of 76.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -98.3 | 41.7% | 92 |
| Total Revenues | 263.4 | 82.4% | 38 |
| Return on Equity | -24.9 | 43.7% | 53 |
The below chart describes Arrowhead Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Arrowhead Pharmaceuticals received a income statement score of 76 , the average of its peers stands on 65.0.
- ARWR
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 3 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 4 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 5 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 7 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 16 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 18 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 20 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 21 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 22 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 23 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 24 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 25 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 26 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 27 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 28 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 29 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 38 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 45 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 51 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 53 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 56 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 64 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 65 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 67 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 68 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 77 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 81 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 93 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Arrowhead Pharmaceuticals appears likely to maintain its strong cash flow metrics and momentum going forward. Arrowhead Pharmaceuticals is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.4, representing a 42.1% change from the previous period. This metric might have a 4.1 percent impact on companies in the same industry and with the same market capitalization. Their impressive asset turnover metrics, specifically in contrast to their industry peers' performance, should support a tailwind in the company's stock price. Correspondingly, their asset turnover movement received a grade of 96. Also, Arrowhead Pharmaceuticals's management was effective in improving its CapEx, which now sits at -22.7 and represents 9.6% change from the previous report. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. Therefore, its CapEx movement component earned a score of 87. That said, one metric, Free Cash flow, stood out as strongly negative. Free cash flow numbers published by Arrowhead Pharmaceuticals were -0.7, which was a -160.4% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. Their free cash flow situation is more concerning relative to their peers and competitors. Disappointing results in free cash flow often lead to negative pressure in stock prices, so we rated their free cash flow with a score of 39. Because its management is doing an excellent job managing these critical metrics, the cash flow was given a score of 70.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -286.0 | -491.7% | 60 |
| Capital Expenditure | -22.7 | 9.6% | 87 |
| Asset Turnover | 0.4 | 42.1% | 96 |
| Free Cashflow | -0.7 | -160.4% | 39 |
The below chart describes Arrowhead Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Arrowhead Pharmaceuticals received a cash flow score of 70, the average of its peers stands on 69.0.
- ARWR
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 3 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 4 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 5 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 7 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 16 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 18 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 20 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 21 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 22 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 23 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 24 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 25 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 26 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 27 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 28 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 29 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 38 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 45 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 51 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 53 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 56 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 64 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 65 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 67 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 68 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 77 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 81 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 93 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.